TraumaShield

PROTECTING MINDS BEFORE TRAUMA TAKES HOLD

Trauma is Inevitable. PTSD is Preventable.

TraumaShield: The World's First Acute Neuro-Prophylaxis for PTSD Prevention

Post -traumatic stress disorder (PTSD) is one of the most devastating and costly mental- health crises.

70%
experience trauma worldwide.

13M+
annual PTSD cases (U.S.).

$232B
total annual economic burden (U.S.).

$19,630
annual cost per affected individual (U.S.).

10-30% of trauma survivors develop chronic **PTSD**

Despite the massive human and economic burden of PTSD, today's treatments remain late-stage and reactive-addressing symptoms only after the damage is done. The critical "golden hours" post-trauma, when memory consolidation can be disrupted and prevention is possible, are completely unaddressed.

The Treatment Gap: Treating the Smoke, Not the Fire



TraumaShield

The World's First Field-Deployed PTSD Prevention Device

The Solution: The Mental Tourniquet

TraumaShield is an innovative first-aid device that delivers a second medical-use, FDA-approved compound immediately after trauma. The treatment rapidly calms the brain's fear-response system, disrupts fear-memory consolidation, and supports healthy contextual memory-preventing PTSD, depression, and anxiety before they form.



Mechanism of Action

The Alarm
(Amygdala)

Suppresses Hyperactivity & Fear Learning



The Context
(Hippocampus)

Blocks Traumatic Memory Consolidation



Dual-target approach to prevent trauma consolidation.

TraumaShield

The World's First Field-Deployed PTSD Prevention Device

The Business Model

Insurers
Value-Based Care

Hospitals, EMS, Trauma Centers

B2G
Stockpile Essential

$19,630/yr → 1:65 ROI → $300

50M Trauma Events × **20%** Target Volume × **$300/** unit =

$3.0 Billion SAM

Traction

- ☑ Phase 2 clinical protocol; PI + pilot centers secured
- ☑ Israeli MoH meeting
- ☑ Independent clinical validation
- ☑ IP strategy finalized; patent filed; patentability cleared
- ☑ Regulatory strategy
- ☑ Full scientific package assembled

2026: validation
- ☐ Phase 2 clinical trial
- ☐ Pre-seed

2027: Expansion
- ☐ Phase 2 primary endpoint
- ☐ Strategic partnerships
- ☐ Device developed
- ☐ Fundraise

2028: growth
- ☐ Pivotal trial launch
- ☐ Defense contracts
- ☐ NDA preparation

2029:Commercialization
- ☐ pivotal trials end goals
- ☐ FDA approval
- ☐ U.S. market entry
- ☐ Scale & marketing

2030: Preventive care standard; Development expansion.

The Team

Joseph Zohar M.D.
CMO

Professor of Psychiatry; former Rambam Psychiatry Director; former IDF Chief of Mental Health; ICAR.

David Slobodiansky
Co-founder, CEO

Psychiatry resident with hands-on clinical experience, M.Sc. in Neuroscience from Oxford

Daniel Kolsky M.D.
Co-founder, Clinical Lead

Senior business strategist; former Sales & Marketing Director; M.Sc. in Neuroscience.

Eyal Fruchter M.D.
VP Clinical Operations

International PTSD expert; former Sheba Psychiatry Director; former President of the European Neuropsychopharmacology Association.

Rethink the Impossible

Backed by an on-site team of neuroscience experts, psychiatrists, clinical and regulatory professionals.

Help us make trauma a memory, not a disorder

Next milestone: Generate real-world evidence with DDR&D, hospitals, and EMS toward FDA approval